Skip to main content

Table 2 Rating scale assessments

From: Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Rating scale
[ … ]
UPDRS Part II (ADL during OFF); mean ± SD
 Baseline (n = 475)17.1 ± 7.0
 3 months (n = 389)13.9 ± 6.8
 Change from baseline (n = 389)− 3.0 ± 4.6
P value vs. baseline< 0.0001
UPDRS Part III (motor scores during ON); mean ± SD
 Baseline (n = 476)26.5 ± 12.1
 3 months (n = 391)21.5 ± 11.0
 Change from baseline (n = 391)− 4.6 ± 8.1
P value vs. baseline< 0.0001
[…]
  1. NMSS Non-motor symptom scale, UPDRS Unified Parkinson’s Disease Rating Scale, PDQ-8 Parkinson’s Disease Questionnaire